Fluidigm Completes Acquisition of DVS Sciences

SOUTH SAN FRANCISCO, Calif. & SUNNYVALE, Calif.--(BUSINESS WIRE)--Fluidigm Corp. (NASDAQ: FLDM) today announced it has completed its
acquisition of DVS Sciences, Inc. With the closing of the acquisition,
Fluidigm adds a high-parameter single-cell protein analysis platform to
its industry-leading single-cell genomics platforms to create a
comprehensive portfolio of advanced technologies serving the rapidly
growing single-cell genomics and proteomics markets.

DVS’s principal product is the CyTOF® 2 Mass Cytometer, which
analyzes antibody/metal complexes using atomic mass spectrometry. The
technology enables high-parameter single-cell protein analysis for
applications in biological research. Several members of DVS’s
management, operations and research and development teams – including
co-founders Scott Tanner, Dmitry Bandura, and Vladimir Baranov – are
joining Fluidigm to drive the integration of the organizations and
support the continued growth of the combined business.

“As evidenced by its products, technology, people and business
trajectory, DVS is an extraordinary company. We are thrilled to have it
become part of Fluidigm,” said Gajus Worthington, Fluidigm President and
Chief Executive Officer. “2013 was an incredible year for Fluidigm as we
took our business and scientific influence to a new level. Now we are
doubling our efforts to take our newly combined company and collective
capabilities to new heights. Fluidigm now offers a comprehensive
portfolio of genomic and proteomic solutions for this new and very
exciting field of single-cell biology.”

DVS Sciences, Inc., with its principal operations in Sunnyvale,
California, is now a wholly-owned subsidiary of Fluidigm. DVS Sciences
Inc., a Canadian corporation with principal operations in Toronto,
Ontario, remains a wholly owned subsidiary of DVS Sciences, Inc.

Forward-Looking Statements

This release contains statements that are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995,
including statements regarding Fluidigm’s completed acquisition of DVS
Sciences, Inc., the prospects for the combined company, the market
opportunity for Fluidigm and DVS Sciences’ products, Fluidigm’s
expectations for the development of the single-cell genomics and
proteomics markets, the introduction of new products in these markets,
and the future growth of our business. Any statements contained in this
press release that are not statements of historical fact may be deemed
to be forward-looking statements. Words such as “believes,”
“anticipates,” “plans,” “expects,” “will,” “intends,” “potential,”
“possible” and similar expressions are intended to identify
forward-looking statements.

Forward-looking statements involve risks and uncertainties related to
the respective businesses of Fluidigm, DVS Sciences, and the combined
company. Forward-looking statements are subject to numerous risks and
uncertainties that could cause actual results to differ materially from
currently anticipated results, including but not limited to risks
arising from the acquisition, such as our lack of experience in
acquiring and integrating new businesses; risks relating to the
integration of DVS Sciences’ business and operations with those of
Fluidigm; the possibility that we will not realize anticipated revenue
and potential operating expense synergies from the proposed acquisition;
the possible loss of key employees, customers, or suppliers as a result
of uncertainty caused by the announcement of the proposed acquisition;
and intellectual property risks arising from the acquisition, including
risks relating to maintaining material in-licensed intellectual property
rights. In addition, Fluidigm’s business and that of DVS Sciences are
subject to numerous additional risks and uncertainties, including, among
others, risks relating to market acceptance of our products; our ability
to successfully launch new products and applications; competition; our
sales, marketing and distribution capabilities; our planned sales,
marketing, and research and development activities; reduction in
research and development spending or changes in budget priorities by
customers; interruptions or delays in the supply of components or
materials for, or manufacturing of, our products; seasonal variations in
customer operations; unanticipated increases in costs or expenses; and
risks associated with international operations. Information on these and
additional risks, uncertainties, and other information affecting our
business and operating results are contained in our Quarterly Report on
Form 10-Q for the quarter ended September 30, 2013, and our other
filings with the Securities and Exchange Commission, including the
Registration Statement on Form S-3ASR recently filed with the Securities
and Exchange Commission. These forward-looking statements speak only as
of the date hereof. Fluidigm Corporation disclaims any obligation to
update these forward-looking statements except as may be required by law.

About Fluidigm

Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets microfluidic
systems to leading academic institutions, clinical laboratories, and
pharmaceutical, biotechnology, and agricultural biotechnology companies
in growth markets, such as single-cell genomics, applied genotyping, and
sample preparation for targeted resequencing. Fluidigm’s proprietary
microfluidic systems consist of instruments and consumables, including
18 different commercial integrated fluidic circuits for nucleic acid
analysis, and three families of assay chemistries. These systems are
designed to significantly simplify experimental workflow, increase
throughput, and reduce costs, while providing the excellent data quality
demanded by customers. Fluidigm products are provided: For Research Use
Only. Not for use in diagnostic procedures.

Fluidigm and the Fluidigm logo are trademarks or registered trademarks
of Fluidigm Corporation.

About DVS Sciences, Inc.

DVS Sciences, Inc. manufactures and globally distributes novel
bioanalytical solutions for use in biomarker discovery, biological
research and potential future use in clinical applications. The patented
multi-parameter technology comprises a high-throughput mass cytometer
for quantitative individual cell analysis, CyTOF, and the suite of
stable isotope-tagged panel kits and reagents. The CyTOF platform
overcomes the limitations of conventional flow cytometry, simplifies
sample preparation, and can simultaneously identify up to 100 biomarkers
with high resolution and wide dynamic range. CyTOF systems are installed
in leading laboratories across the U.S., Canada, Europe and Asia. DVS
Sciences has its global headquarters and reagent kit manufacturing in
Sunnyvale, California with a R&D and instrument manufacturing facility
near Toronto, Canada, and a sales/support office in the UK.

DVS Sciences and CyTOF are trademarks or registered trademarks of DVS
Sciences, Inc.